Repurposing the Repurposing Business Model

Two recent examples of the difficulties of drug repurposing: Bionaut's ability to find new indications was not sufficient to get a foot in pharma's door without novelty to create barriers to entry to deter fast followers. Sention couldn't generate data fast enough on its L-amphetamine in improving cognitive impairment to counter amphetamine's bad image. (Its second program, even armed with pharma-vetted, baggage-less NCEs in-licensed from Merck, emerged too late to save the company.)